01—Abstract
Summary
Summary of the 8-K filed July 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. reported second-quarter 2025 revenue of $603.3 milliona, up 14.2% from $528.1 million a year earlier.
GAAP net income was $90.3 millionb, or $3.10 per diluted share, compared with $88.4 million, or $2.75 per diluted share, in the prior-year quarter. Net income margin fell to 15.0% from 16.7%, while EBITDA rose 16.2% to $130.5 million, with an EBITDA margin of 21.6%. Net new business awards were $620.5 million, up 12.6%, for a net book-to-bill ratio of 1.03x.
Backlog decreased 1.8% to $2,873.6 millionc as of June 30, 2025. The company raised its 2025 outlook in the form given: revenue of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. It also forecasts GAAP net income of $405.0 million to $428.0 million, EBITDA of $515.0 million to $545.0 million, and diluted EPS of $13.76 to $14.53.
The guidance assumes a tax rate of 18.5% to 19.0% and 29.4 million diluted weighted average shares, and excludes any share repurchases after June 30, 2025. Capital allocation was heavy during the period. Medpace repurchased 1,754,264 shares in the second quarter at an average price of $295.59d, for $518.5 million, and $908.4 million year to date.
Cash and cash equivalents were $46.3 million at June 30, 2025, compared with $669.4 million at December 31, 2024, and $826.3 million remained under the share repurchase authorization. The filing also reports an amendment to the PNC Bank unsecured credit facility, under which the line of credit may be borrowed up to $10 million. The earnings release is furnished under Item 2.02 and is not deemed filed for Section 18 purposes.
02—Key points
Key Highlights
- Q2 2025 revenue of $603.3 million, up 14.2% from $528.1 million; constant currency revenue growth of 13.8%.
- Net new business awards of $620.5 million, up 12.6%, for a net book-to-bill ratio of 1.03x; backlog of $2,873.6 million, down 1.8% year over year.
- Q2 GAAP diluted EPS of $3.10 versus $2.75; net income margin of 15.0% versus 16.7%.
- Q2 EBITDA of $130.5 million, up 16.2%, with a 21.6% EBITDA margin; year-to-date EBITDA of $249.1 million.
- 2025 guidance: revenue of $2.420 billion to $2.520 billion, GAAP net income of $405.0 million to $428.0 million, and diluted EPS of $13.76 to $14.53.
- Share repurchases of $518.5 million in Q2 and $908.4 million year to date; $826.3 million remained under the authorization at June 30, 2025.
- Cash and cash equivalents fell to $46.3 million at June 30, 2025, from $669.4 million at December 31, 2024; Amendment No. 9 to the PNC credit facility sets the line of credit at up to $10 million.
03—Questions
Frequently Asked Questions
How did Medpace perform in the second quarter of 2025?
Revenue rose 14.2% to $603.3 million, and GAAP net income was $90.3 million, or $3.10 per diluted share, versus $88.4 million, or $2.75 per diluted share, a year earlier. EBITDA grew 16.2% to $130.5 million, with a 21.6% margin. Net income margin declined to 15.0% from 16.7%.
What is the company's demand and backlog position?
Net new business awards were $620.5 million in the second quarter, up 12.6% from $551.0 million, for a net book-to-bill ratio of 1.03x. Backlog was $2,873.6 million at June 30, 2025, down 1.8% from $2,924.9 million a year earlier.
What guidance did Medpace give for 2025?
The company forecasts 2025 revenue of $2.420 billion to $2.520 billion, growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. It expects GAAP net income of $405.0 million to $428.0 million, EBITDA of $515.0 million to $545.0 million, and diluted EPS of $13.76 to $14.53. The guidance excludes share repurchases after June 30, 2025.
How much capital did Medpace return to shareholders and how much cash remains?
Medpace repurchased $518.5 million of stock in the second quarter and $908.4 million year to date, including 2,947,275 shares for the six months. As of June 30, 2025, $826.3 million remained under the authorization. Cash and cash equivalents were $46.3 million at June 30, 2025, compared with $669.4 million at December 31, 2024.
What did the company disclose about its credit facility?
Medpace, through subsidiaries Medpace, Inc. and Medpace IntermediateCo, Inc., entered into Amendment No. 9 to the loan documents with PNC Bank, National Association, on July 17, 2025. The amendment changes the aggregate principal amount that may be borrowed under the line of credit to up to $10 million.
04—Continue